SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
A crossover study from a standard-dose to a low-dose oral contraceptive was conducted in the Sudan. Reported side effects were very few, with a headache the most frequently reported. Switching to the other pill did not affect the rate of any side effects.
Twenty-seven breastfeeding mothers and nine non-breastfeeding postpartum comparison mothers in Bangkok, Thailand were followed longitudinally until ovulation resumed. A simple set of guidelines is described involving three obvious milestones for the breastfeeding mother to safely use the natural contraceptive benefit of breastfeeding. Those milestones are the first menses, the initiation of supplementation and the child's monthly birthday. In the absence of menses and supplementation, 93% of breastfeeding mothers remained anovular for 3 months postpartum and 88-89% for up to 6 months. Further, the work of other investigators suggests that the proportion ovulatory provides an overestimate of those at risk of pregnancy. The guidelines suggest a way to estimate the period of lactational infertility and may be most useful on a programmatic level.
Reports of state in relation to the menstrual cycle were investigated using daily measures of state in a group of 65 family planning clinic attenders without pre-existing menstrual complaint. Women reported significant changes in their physical and psychological state prior to menstruation which reverted to "normal' levels 3-5 days after the onset of menstruation. No statistically significant differences were found between the patterns of oral contraceptive users and non-users.
The relation between the use of oral contraceptives and changes in positive and negative affect over the course of the menstrual cycle was studied in 50 women who completed a mood questionnaire daily during their menstrual cycle. Results indicated that users of oral contraceptives experience a higher level of positive affect during the cycle than do non-users. Positive affect scores were significantly higher than negative affect scores in the menstruation, follicular and luteal phases of the cycle. There were no significant differences between the groups and no discernible phasic changes on negative affect. Discussion of these findings centers on their implications concerning the relation between positive affect and oral contraceptives, the support they provide for the independence of positive and negative affect, and future directions for research in this area.
Eighty-two women with complaints of moderate to severe premenstrual symptoms were recruited for a double-blind, controlled trial of a triphasic oral contraceptive (o.c.). Subjects made daily ratings of symptoms for at least one baseline cycle and were then randomly assigned to receive either placebo or o.c. for three months. Twenty-three women dropped out of the study (18 o.c., 5 placebo), 13 failed to show prospective confirmation of moderate to severe premenstrual symptoms, and one placebo subject had an anovulatory cycle. Forty-five women with prospectively-confirmed premenstrual changes (20 o.c., 25 placebo) completed the study. Premenstrual breast pain and bloating were significantly reduced with active treatment compared to placebo (p less than 0.03) but there were no beneficial effects of the o.c. over placebo for any of the mood symptoms. Women who received o.c.s reported decreased sexual interest after starting treatment and this effect was independent of any adverse influence on mood.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Two formulations of polylactic and polyglycolic acid microcapsules containing 75 and 100 mg of NET respectively were studied for a 90-day period of anticipated contraceptive effect in two groups of five women. A 200 mg dose of NET preparation was also studied for a 180-day period of anticipated contraceptive effect in 19 women. Alteration in menstrual cycle, with tendency to short bleeding episodes, spotting days, and amenorrhea were the most important collateral effects. In the majority of cases, ovulation was inhibited. No cases of pregnancy were presented. The obtained NET circulating levels were very stable during the period of anticipated contraceptive effect.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Prolactin is a mammotropic hormone essential for the initiation of lactation. It also influences ovarian function; during hyperprolactinemia hypogonadism occurs. This is true for pathological forms of hyperprolactinemia but also for the early puerperium when there is physiological hyperprolactinemia. Amenorrhea is a better parameter of hyperprolactinemia than galactorrhea. The mechanisms by which prolactin disrupts ovarian function are not as yet fully understood; it probably alters hypothalamic neurotransmitter content through a direct feedback mechanism resulting in a decrease of Gn-RH. However, the direct effect of prolactin-producing pituitary tumors on the capacity of the gonadotrophs or a direct interference of prolactin at the gonadal level are also possibilities. Hyperprolactinemia can be treated very effectively with bromocriptine and this drug appears to have become the favorite form of treatment. In the case of obvious tumors hypophysectomy is indicated. When there are smaller tumors irradiation of the pituitary gland previous to bromocriptine treatment may prevent expansion of the gland during subsequent pregnancy.
Explore the source record for details and available documents.
The influence of clomiphene citrate was tested in 206 women suffering from menorrhagia following the insertion of an intrauterine device (IUD). Eighty-three percent felt relief during the therapy, 10% did not benefit and 7% complained of a worsening of their symptoms. Among the women who felt an improvement, 85% responded to the 250 mg/cycle dosage, and 15% required the 350 mg/cycle dosage. Women with shortened menstrual cycles required the higher dose treatment, i.e. 350 mg, compared with women with normal cycles (36% vs. 28%, respectively). The influence of placebo was 6%. The hypothesis is raised that the mechanism of action of clomiphene citrate is the correction of the hormonal disturbances in the luteal phase of the cycle following insertion of the IUD.
Seventy-five patients with ectopic pregnancy were treated at Jordan University Hospital (JUH) during a 7-yr period from January 1976 to December 1982. The ratio of ectopic pregnancies to deliveries was 1 to 162. The most common symptoms were: abdominal pain, 96%; amenorrhea, 69.3%; vaginal bleeding, 60%. No patients with pelvic inflammatory disease were found. An intrauterine contraceptive device was present in 14.6% of the patients and 10.6% of the cases had previous pelvic surgery. Culdocentesis gave false negative results in 16.7% of the patients. The treatment of choice was salpingectomy. There were no maternal deaths in this series.
A separate clinical and ultrasound study was carried out in 20 unselected patients receiving an IUD (ML Cu 250 or Cu T-200). Clinical adverse effects were studied in relation to ultrasound findings after 0, 2 and 6 months of insertion. Using both the sound length and initial ultrasound measurements, it was possible to calculate that none of the 20 IUDs reached the fundal wall of the uterine cavity (distance 0.1-2.4 cm). The mean initial distance between the top of the uterine fundal wall and the top of the IUD (TOP) was 2.0 cm (range 1.3-2.4 cm). A downward displacement of more than 0.5 cm in consecutive measurements was observed in 3 patients. Malposition of one or two arms of the IUD was found in 8 patients. In 6 of these patients clinical complaints were present.
Nine oligomenorrheic adolescent girls with a clinical and hormonal picture of ovarian hyperandrogenism were treated with a monophasic oral contraceptive (OC) containing 0.03 mg ethinylestradiol (EE) plus 0.150 mg desogestrel (DOG) for six months. The same treatment was administered in eight eumenorrheic adolescents. In both groups the treatment induced a decrease in LH, FSH, androstenedione (delta 4-A), testosterone (T) and dehydroepiandrosterone sulphate (DHEA-S) levels associated with a significant sex-hormone-binding globulin (SHBG) increase. In oligomenorrheic adolescents a marked decrease in both the total ovarian volume and the number of cystic follicles was observed. All parameters, except SHBG and ovarian volume in hyperandrogenic girls, returned to pre-treatment values 3 months after treatment. Subjective improvement of skin problems occurred in six of the nine oligomenorrheic girls. Although temporary, the EE + DOG formulation pill is effective in the treatment of ovarian hyperandrogenism in adolescents. It may also be useful for the prevention of the progressive transformation in the 'classical' and 'irreversible' micropolycystic ovary of adult age.